Plus: BYDUREON Pen to be discontinued; canagliflozin plus liraglutide effects; more
Tuesday, Sept. 29, 2020 : Issue #1067 DISASTERS AVERTED — Near Miss Case Studies
Patient's Method of Figuring Meal-time Insulin Doesn't Quite Work |
|
Letter from the Editor
When we add medications for our patients, our focus is usually directed by such things as A1C, Time in Range, maximum highs and the like. However, when we add these medications we often don’t see a noticeable difference in the aforementioned parameters.
A good example of how adding medications that don’t necessarily affect a specific target works is seen in a new article that David Clarke, PharmD Candidate, University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, has prepared for us.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
| |
|
|
|
Newsflash: BYDUREON Pen to Be Discontinued
Effective March 2021, AstraZeneca will discontinue distribution of BYDUREON Pen. Patients should be switched to Bydureon BCise.
Coming Oct 6th! Special Report:
The first installment of "The Future of Type 2 Diabetes Management and The Changing Roles of Healthcare Professionals."
Adherence-related issues are hemorrhaging the costs of diabetes-related treatment in America. To offset this tragedy, GlucosePATH is utilized by a team of healthcare professionals dedicated to improving the quality of life while decreasing avoidable costs. Don't miss this special feature, exclusively in Diabetes in Control. |
DISASTERS AVERTED — Near Miss Case Studies |
|
| Patient's Method of Figuring Meal-time Insulin Doesn't Quite Work
Recently I assessed an 84-year-old inpatient with diabetes for his insulin usage at home. In reporting his dosing, he stated that after he checked his glucose before each meal, he took the "first two numbers of the result," and made his dosage for meal-time insulin.... |
| |
|
|
TOP STORIES - Diabetes News and Research |
|
| |
|
|
|
| | | | About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control. |
| Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com |
|
|
|
|
| | |
|
|
|
|
